Antisense Products: Technology, Markets

Introduction
Reasons For The Study

Objectives Of The Study

Audience For The Study

Scope And Content Of The Study

Methodology Used In Study

Analyst Credentials

Related Bcc Reports

Monthly Newsletters

Bcc On-Line Services

Summary
Summary Table:
Potential Market For Antisense Therapeutics, 2007 ($ Billions)

Summary Figure:
Distribution Antisense Therapeutics Market Value By Application, 2007 ($ Millions)

Antisense Technologies Overview
Gene Expression

The Process Of Gene Expression

Step One: Signaling

Figure 1. Signaling To Begin Expression Of A Gene

Step Two: Unwinding Of Dna

Figure 2. Unwinding And Separation Of Dna Strands

Step Three: Transcription

Figure 3. Rna Transcription

Step Four: Rna Processing

Figure 4. Rna Splicing

Step Five: Translation

Figure 5. Translation Of A Protein

How Antisense Controls Gene Expression

Figure 6. Hybridization Of Antisense Oligo To Mrna

Blocking Of Mrna Splicing

Figure 7. Hybridized Oligo Interferes With Splicing

Blocking Ribosomes

Figure 8. Antisense Oligo Inhibition Of Ribosomes

Rnase H Cleavage Of Mrna

Figure 9. Rnase H Digestion Of Rna-Dna Duplex

Chemistry Of Antisense Compounds

The Original Antisense Compounds

Figure 10. Structure Of Dna And Rna

First Generation Antisense Compounds

Figure 11. First Generation Of Antisense Molecules

Second Generation Antisense Compounds

Figure 12. Second Generation Antisense Modifications

2'-Ribose Modifications

N 3' To P 5' Modifications

Phosphorodiamidate Morpholino Modifications

Peptide Nucleic Acids (Pnas)

Ribozymes

Figure 13. Ribozymes

Hammerhead Ribozymes

Hairpin Ribozymes

History Of Antisense Technology

Figure 14. Number Of Antisense Scientific Publications, 1973-2002

Antisense Therapeutics Applications
Cancer

Brain Cancer

Breast Cancer

Colorectal Cancer

Kidney Cancer

Leukemia

Lung Cancer

Lymphoma

Skin Cancer

Multiple Myeloma

Ovarian Cancer

Pancreatic Cancer

Prostate Cancer

Overview Of Current Cancer Treatment Strategies

Antisense Cancer Treatment Strategies

Table 1. Antisense Products For Treatment Of Cancer

Coronary Heart Disease

Restenosis

Overview Of Current Treatments

Antisense Treatments For Restenosis

Table 2. Antisense Products For Treatment Of Restenosis

Diabetes

Type 2 Diabetes

Current Treatments For Type 2 Diabetes

Antisense Treatment For Type 2 Diabetes

Table 3. Antisense Products For Treatment Of Type 2 Diabetes

Immunological Disorders

Asthma

Crohn's Disease And Ulcerative Colitis

Multiple Sclerosis

Psoriasis

Rheumatoid Arthritis

Current Treatment For Immunological Disorders

Antisense Treatments For Immunological Disorders

Table 4. Antisense Products For Treatment Of Immunological Disorders

Infectious Diseases

Cytomegalovirus/Retinitis

Hepatitis B

Hepatitis C

Human Immunodeficiency Virus

Human Papillomavirus

Current Treatment Of Infectious Diseases

Antisense Treatment For Infectious Diseases

Table 5. Antisense Products For Treatment Of Infectious Diseases

Polycystic Kidney Disease

Polycystic Kidney Disease

Current Treatments For Polycystic Kidney Disease

Antisense Treatment For Polycystic Kidney Disease

Retinal Disorders

Age-Related Macular Degeneration

Diabetic Retinopathy

Proliferative Vitreoretinopathy

Current Treatments For Retina Disorders

Antisense Treatment For Retinal Disorders

Table 6. Antisense Products For Treatment Of Retinal Disorders

Antisense Therapeutics Products
Aegera Therapeutics Inc.

Antisense Xiap (X-Linked Inhibitor Of Apoptosis)

Type Of Antisense Technology

Stage Of Development

Angiogene Inc.

Oliglow™

Type Of Antisense Technology

Stage Of Development

Antisense Pharma Gmbh

Ap 12009

Type Of Antisense Technology

Stage Of Development

Antisense Therapeutics Ltd.

Atl 1101

Type Of Antisense Technology

Stage Of Development

Atl 1102

Type Of Antisense Technology

Stage Of Development

Avi Biopharma

Avi 4014

Type Of Antisense Technology

Stage Of Development

Avi 4126

Type Of Antisense Technology

Stage Of Development

Avi 4557

Type Of Antisense Technology

Stage Of Development

Oncomyc-Ng

Type Of Antisense Technology

Stage Of Development

Table 7. Clinical Trial Status Of Antisense Therapeutic Oncomyc

Restine-Ng

Type Of Antisense Technology

Stage Of Development

Enzo Therapeutics

Hgtv-43

Type Of Antisense Technology

Stage Of Development

Epigenesis Pharmaceuticals, Inc.

Durason™ (Epi-2010)

Type Of Antisense Technology

Stage Of Development

Genta

Genasense™

Type Of Antisense Technology

Stage Of Development

Table 8. Clinical Trial Status Of Antisense Therapeutic Genasense™

Hybridon, Inc.

Antisense Epidermal Growth Factor Receptor

Type Of Antisense Technology

Stage Of Development

Antisense Nucleotide Excision Repair Protein Xpa

Type Of Antisense Technology

Stage Of Development

Antisense Survivin

Type Of Antisense Technology

Stage Of Development

Gem®92

Type Of Antisense Technology

Stage Of Development

Gem®220

Type Of Antisense Technology

Stage Of Development

Gem®231

Type Of Antisense Technology

Stage Of Development

Table 9. Clinical Trial Status Of Antisense Therapeutic Gem®231

Gem®240

Type Of Antisense Technology

Stage Of Development

Immusol Inc.

Proliferase™

Type Of Antisense Technology

Stage Of Development

Restenase™

Type Of Antisense Technology

Stage Of Development

Vitrenase™

Type Of Antisense Technology

Stage Of Development

Isis Pharmaceuticals

Affinitac™ (Isis 3521)

Type Of Antisense Technology

Stage Of Development

Table 10. Clinical Trial Status Of Antisense Therapeutic Affinitac™

Alicaforsen (Isis 2302)

Type Of Antisense Technology

Stage Of Development

Table 11. Clinical Trial Status Of Antisense Therapeutic Alicaforsen

Isis 2503

Type Of Antisense Technology

Stage Of Development

Table 12. Clinical Trial Status Of Antisense Therapeutic Isis 2503

Isis 13650

Type Of Antisense Technology

Stage Of Development

Isis 14803

Type Of Antisense Technology

Stage Of Development

Isis 104838

Type Of Antisense Technology

Stage Of Development

Table 13. Clinical Trial Status Of Antisense Therapeutic Isis 104828

Isis 113715

Type Of Antisense Technology

Stage Of Development

Vitravene™ (Fomivirsen)

Type Of Antisense Technology

Stage Of Development

Lorus Therapeutics

Gti 2040

Type Of Antisense Technology

Stage Of Development

Table 14. Clinical Trial Status Of Antisense Therapeutic Gti 2040

Gti 2501

Type Of Antisense Technology

Stage Of Development

Methylgene

Mg 98

Type Of Antisense Technology

Stage Of Development

Neopharm

Leraf-Aon

Type Of Antisense Technology

Stage Of Development

Oncogenex Therapeutics

Ogx-011

Type Of Antisense Technology

Stage Of Development

Table 15. Clinical Trial Status Of Antisense Therapeutic Ogx-011

Origenix Technologies

Ori-1001

Type Of Antisense Technology

Stage Of Development

Panacea Pharmaceuticals

Pan 346

Type Of Antisense Technology

Stage Of Development

Ribozyme Pharmaceuticals

Angiozyme®

Type Of Antisense Technology

Stage Of Development

Table 16. Clinical Trial Status Of Antisense Therapeutic Angiozyme®

Hepbzyme™

Type Of Antisense Technology

Stage Of Development

Heptazyme™

Type Of Antisense Technology

Stage Of Development

Herzyme™

Type Of Antisense Technology

Stage Of Development

Markets For Antisense Therapeutics Applications
Cancer Therapeutics

Table 17. Incidence Of Cancer In The U.S., Through 2007 (Number Of Cases)

Figure 15. Incidence Of Types Of Cancers, 2002, 2002 And 2007 (Number Of Cases)

Table 18. Market For Cancer Therapeutics In The U.S., Through 2007 ($ Billions)

Table 19. Cost Of Cancer Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Restenosis Therapeutics

Table 20. Stents Used In Angioplasty Procedures, Through 2007 (Millions Of Units)

Table 21. Cost Of Stents In The U.S., Through 2007 ($/Stent)

Table 22. Market For Stents In The U.S., Through 2007 ($ Billions)

Type 2 Diabetes Therapeutics

Table 23. Prevalence Of Type 2 Diabetes, Through 2007 (Thousands Of Cases)

Table 24. Cost Of Type 2 Diabetes Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 25. Market For Type 2 Diabetes Therapeutics In The U.S., Through 2007 ($ Billions)

Immunological Disorder Therapeutics

Table 26. Prevalence Of Immunological Disorders Potential Treated With Antisense Therapeutics, Through 2007 (Thousand Cases)

Figure 16. Prevalence Of Immunological Disorders, 2002, 2002 And 2007 (Thousand Cases)

Table 27. Market For Therapeutics For Immunological Disorders, Through 2007 ($ Billions)

Asthma

Table 28. Cost Of Asthma Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 29. Market For Asthma Therapeutics In The U.S., Through 2007 ($ Billions)

Crohn's Disease And Ulcerative Colitis

Table 30. Cost Of Crohn's Disease And Ulcerative Colitis Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 31. Market For Crohn's Disease And Ulcerative Colitis Therapeutics In The U.S., Through 2007 ($ Billions)

Multiple Sclerosis

Table 32. Cost Of Multiple Sclerosis Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 33. Market For Multiple Sclerosis Therapeutics In The U.S., Through 2007 ($ Billions)

Psoriasis

Table 34. Cost Of Psoriasis Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 35. Market For Psoriasis Therapeutics In The U.S., Through 2007 ($ Billions)

Rheumatoid Arthritis

Table 36. Cost Of Rheumatoid Arthritis Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 37. Market For Rheumatoid Arthritis Therapeutics In The U.S., Through 2007 ($ Billions)

Infectious Disease Therapeutics

Table 38. Prevalence Of Viral Diseases Potentially Treated With Antisense Therapeutics, Through 2007 (Thousand Cases)

Figure 17. Prevalence Of Viral Disease, 2000, 2002 And 2007 (Thousand Cases)

Table 39 Market For Infectious Disease Therapeutics, Through 2007 ($ Billions)

Cytomegalovirus (Cmv) Retinitis

Table 40. Cost Of Cmv Retinitis Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 41. Market For Cmv Retinitis Therapeutics In The U.S., Through 2007 ($ Millions)

Hepatitis B Virus (Hbv)

Table 42. Cost Of Hbv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 43. Market For Hbv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($ Billions)

Hepatitis C Virus (Hcv)

Table 44. Cost Of Hcv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 45. Market For Hcv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($ Billions)

Human Immunodeficiency Virus (Hiv)

Table 46. Cost Of Hiv Infections Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 47. Market For Hiv Infections Therapeutics In The U.S., Through 2007 ($ Billions)

Human Papillomavirus (Hpv)

Table 48. Cost Of Hpv Infections Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 49. Market For Hpv Infections Therapeutics In The U.S., Through 2007 ($ Billions)

Polycystic Kidney Therapeutics

Table 50. Prevalence Of Polycystic Kidney Disease, Through 2007 (Number Of Cases)

Table 51. Cost Of Polycystic Kidney Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 52. Market For Polycystic Kidney Disease Therapeutics In The U.S., Through 2007 ($ Billions)

Retina Disorders Therapeutics

Table 53. Prevalence Of Retinal Disorders, Through 2007 (Thousand Cases)

Figure 18. Prevalence Of Retinal Disorders, 2000-2007 (Thousand Cases)

Table 54. Market For Retinal Disorders Therapeutics In The U.S., Through 2007 ($ Billions)

Age-Related Macular Degeneration (Amd)

Table 55. Cost Of Age-Related Macular Degeneration Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 56. Market For Age-Related Macular Degeneration Therapeutics In The U.S., Through 2007 ($ Billions)

Diabetic Retinopathy (Dr)

Table 57. Cost Of Diabetic Retinopathy Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 58. Market For Diabetic Retinopathy Therapeutics In The U.S., Through 2007 ($ Billions)

Proliferative Vitreoretinopathy (Pvr)

Table 59. Cost Of Proliferative Vitreoretinopathy Therapeutics In The U.S., Through 2007 ($/Patient/Year)

Table 60. Market For Proliferative Vitreoretinopathy Therapeutics In The U.S., Through 2007 ($ Billions)

Potential Markets For Antisense Therapeutics

Cancer

Table 61. Antisense Cancer Therapeutics Market, 2007 ($ Millions)
Cancer (Continued)

Restenosis

Table 62. Antisense Anti-Restenosis Therapeutics Market, 2007 ($ Millions)

Type 2 Diabetes

Immunological Disorders

Table 63. Antisense Immunological Disorder Therapeutics Markets, 2007 ($ Millions)

Infectious Diseases

Table 64. Antisense Infectious Disease Therapeutics Market, 2007 ($ Millions)

Polycystic Kidney Disease

Table 65. Antisense Polycystic Kidney Disease Therapeutics Market, 2007 ($ Millions)

Retinal Disorders

Table 66. Antisense Retinal Disorders Therapeutics Market, 2007 ($ Millions)

Total Potential Market For Antisense Therapeutics

Table 67. Potential Market For Antisense Therapeutics, 2007 ($ Millions)

The Technology Behind Antisense Products
New Developments In Antisense Technology

Therapeutic Discovery, Target Validation, And Gene Function

Table 68. Developer Of Drug Discovery Antisense Applications

Patents

Patent Categories

Chemistry

Drug Discovery

Table 69. U.S. Antisense And Related Technology Patents

Therapeutics

Other

Antisense Industry Structure And Completive Profile
Antisense Industry Structure

Worldwide Distribution Of Antisense Therapeutics Developers

Table 70. Companies Developing Antisense Products

Table 70. (Continued)

Figure 19. Worldwide Distribution Of Developers Of Antisense Therapeutics, 2002 (%)

Application Of Antisense Therapeutics

Figure 20. Distribution Of Antisense Therapeutics By Application, 2002 (%)

Table 71. Applications For Antisense Therapeutics

Development And Regulatory Environment Of Antisense Therapeutics

Development Of Therapeutic Agents

Table 72. Development Stages Of Therapeutic Agents

The Development Of Therapeutic Agents

Research And Discovery

Preclinical Development

Phase I Clinical Trials

Phase Ii Clinical Trials

Phase Iii Clinical Trials

Approval Phase

Antisense Therapeutic Development

Figure 21. Distribution Of Antisense Products Development Stage (%)

Figure 21. (Continued)

Table 73. Stage Of Development Of Antisense Products

Table 73. (Continued)

Strategic Alliances And Partnership

Angiogene Inc.

Abbott Vascular

Antisense Pharma

Biognostik Gmbh

Antisense Therapeutics

Isis Pharmaceuticals

Murdoch Children's Research Institute

Avi Biopharma

Medtronic

Exelixis Inc.

Epigenesis Pharmaceutical

Taisho Pharmaceuticals

Chiesi Farmaceutici S.P.A.

Hybridon

Genta

Aventis

Hybridon

Epigenesis Pharmaceuticals

Methylgene

Micrologix Biotech

Origenix Technologies

Immusol

Chugai Pharma Usa Llc

Vertex Pharmaceuticals

Novartis

Isis Pharmaceuticals

Abbott Laboratories

Amgen Inc.

Celera Genomic Group

Elan Partnerships

Novartis Ophthalmic

Methylgene Inc.

Mgi Pharma

Oncogenex Technologies

Isis Pharmaceuticals

Origenix Technology

Ribozyme Pharmaceuticals

Archemix

Strategies Of Leading Antisense Companies

Company Profiles
Aegera Therapeutics Inc.

Angiogene Inc.

Antisense Pharma Gmbh

Antisense Therapeutics Ltd.

Atugen Ag

Avi Biopharma

Benitec Australia Limited

Biognostik Gmbh

Enzo Therapeutics

Epigenesis Pharmaceuticals

Exegenics Inc.

Genta Inc.

Hybridon Inc.

Immusol Inc.

Inex Pharmaceutical Corp.

Isis Pharmaceuticals

Lorus Therapeutics Inc.

Methylgene Inc.

Micrologix Biotech Inc.

Neopharm Inc.

Oncogenex Technologies

Origenix Technologies

Panacea Pharmaceuticals

Patheco A/S

Ribozyme Pharmaceuticals Inc.

Sequitur Inc.

Salus Therapeutics

Salus Therapeutics (Continued)

Appendix A Company By Type Of Antisense Product
Table 74. Company And Type Of Antisense Products

Appendix B
Patent Summaries

Aegera Therapeutics

Table 75. Antisense Patent Portfolio Of Aegera Therapeutics

Angiogene Inc.

Table 76. Antisense Patent Portfolio Of Angiogene

Antisense Pharma

Table 77. Antisense Patent Portfolio Of Antisense Pharma

Avi Biopharma

Table 78. Antisense Patent Portfolio Of Avi Biopharma

Table 78. (Continued)

Epigenesis Pharmaceuticals

Table 79. Antisense Patent Portfolio Of Epigenesis

Genta Inc.

Table 80. Antisense Patent Portfolio Of Genta

Hybridon Inc.

Table 81. Antisense Patent Portfolio Of Hybridon

Immusol Inc.

Table 82. Antisense Patent Portfolio Of Immusol
Isis Pharmaceuticals

Table 83. Antisense Patent Portfolio Of Isis Pharmaceuticals

Lorus Therapeutics

Table 84. Antisense Patent Portfolio Of Lorus Therapeutics

Methylgene Inc.

Table 85. Antisense Patent Portfolio Of Methylgene

Table 85. (Continued)

Ribozyme Pharmaceuticals

Table 86. Antisense Patent Portfolio Of Ribozyme Pharmaceuticals

Table 86. (Continued)

Table 86. (Continued)

Table 86. (Continued)

Table 86. (Continued)

List Of Tables

Summary Table:
Potential Market For Antisense Therapeutics In 2007 ($ Billions)
Table 1 Antisense Products For Treatment Of Cancer
Table 2 Antisense Products For Treatment Of Restenosis
Table 3 Antisense Products For Treatment Of Type 2 Diabetes
Table 4 Antisense Products For Treatment Of Immunological Disorders
Table 5 Antisense Products For Treatment Of Infectious Diseases
Table 6 Antisense Products For Treatment Of Retinal Disorders
Table 7 Clinical Trial Status Of Antisense Therapeutic Oncomyc
Table 8 Clinical Trial Status Of Antisense Therapeutic Genasense™
Table 9 Clinical Trial Status Of Antisense Therapeutic Gem®231
Table 10 Clinical Trial Status Of Antisense Therapeutic Affinitac™
Table 11 Clinical Trial Status Of Antisense Therapeutic Alicaforsen
Table 12 Clinical Trial Status Of Antisense Therapeutic Isis 2503
Table 13 Clinical Trial Status Of Antisense Therapeutic Isis 104828
Table 14 Clinical Trial Status Of Antisense Therapeutic Gti 2040
Table 15 Clinical Trial Status Of Antisense Therapeutic Ogx-011
Table 16 Clinical Trial Status Of Antisense Therapeutic Angiozyme®
Table 17 Incidence Of Cancer In The U.S., Through 2007 (Number Of Cases)
Table 18 Market For Cancer Therapeutics In The U.S., Through 2007 ($ Billions)
Table 19 Cost Of Cancer Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 20 Stents Used In Angioplasty Procedures, Through 2007 (Millions Of Units)
Table 21 Cost Of Stents In The U.S., Through 2007 ($/Stent)
Table 22 Market For Stents In The U.S., Through 2007 ($ Billions)
Table 23 Prevalence Of Type 2 Diabetes, Through 2007 (Thousands Of Cases)
Table 24 Cost Of Type 2 Diabetes Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 25 Market For Type 2 Diabetes Therapeutics In The U.S., Through 2007 ($ Billions)
Table 26 Prevalence Of Immunological Disorders Potential Treated With Antisense Therapeutics, Through 2007 (Thousand Cases)
Table 27 Market For Therapeutics For Immunological Disorders, Through 2007 ($ Billions)
Table 28 Cost Of Asthma Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 29 Market For Asthma Therapeutics In The U.S., Through 2007 ($ Billions)
Table 30 Cost Of Crohn's Disease And Ulcerative Colitis Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 31 Market For Crohn's Disease And Ulcerative Colitis Therapeutics In The U.S., Through 2007 ($ Billions)
Table 32 Cost Of Multiple Sclerosis Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 33 Market For Multiple Sclerosis Therapeutics In The U.S., Through 2007 ($ Billions)
Table 34 Cost Of Psoriasis Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 35 Market For Psoriasis Therapeutics In The U.S., Through 2007 ($ Billions)
Table 36 Cost Of Rheumatoid Arthritis Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 37 Market For Rheumatoid Arthritis Therapeutics In The U.S., Through 2007 ($ Billions)
Table 38 Prevalence Of Viral Diseases Potentially Treated With Antisense Therapeutics, Through 2007 (Thousands Of Cases)
Table 39 Market For Infectious Disease Therapeutics, Through 2007 ($ Billions)
Table 40 Cost Of Cmv Retinitis Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 41 Market For Cmv Retinitis Therapeutics In The U.S., Through 2007 ($ Millions)
Table 42 Cost Of Hbv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 43 Market For Hbv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($ Billions)
Table 44 Cost Of Hcv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 45 Market For Hcv Infections And Chronic Disease Therapeutics In The U.S., Through 2007 ($ Billions)
Table 46 Cost Of Hiv Infections Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 47 Market For Hiv Infections Therapeutics In The U.S., Through 2007 ($ Billions)
Table 48 Cost Of Hpv Infections Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 49 Market For Hpv Infections Therapeutics In The U.S., Through 2007 ($ Billions)
Table 50 Prevalence Of Polycystic Kidney Disease, Through 2007 (Cases)
Table 51 Cost Of Polycystic Kidney Disease Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 52 Market For Polycystic Kidney Disease Therapeutics In The U.S., Through 2007 ($ Billions)
Table 53 Prevalence Of Retinal Disorders, Through 2007 (Thousand Cases)
Table 54 Market For Retinal Disorders Therapeutics In The U.S., Through 2007 ($ Billions)
Table 55 Cost Of Age-Related Macular Degeneration Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 56 Market For Age-Related Macular Degeneration Therapeutics In The U.S., Through 2007 ($ Billions)
Table 57 Cost Of Diabetic Retinopathy Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 58 Market For Diabetic Retinopathy Therapeutics In The U.S., Through 2007 ($ Billions)
Table 59 Cost Of Proliferative Vitreoretinopathy Therapeutics In The U.S., Through 2007 ($/Patient/Year)
Table 60 Market For Proliferative Vitreoretinopathy Therapeutics In The U.S., Through 2007 ($ Billions)
Table 61 Antisense Cancer Therapeutics Market, 2007 ($ Millions)
Table 62 Antisense Anti-Restenosis Therapeutics Market, 2007 ($ Millions)
Table 63 Antisense Immunological Disorder Therapeutics Markets, 2007 ($ Millions)
Table 64 Antisense Infectious Disease Therapeutics Market, 2007 ($ Millions)
Table 65 Antisense Polycystic Kidney Disease Therapeutics Market, 2007 ($ Millions)
Table 66 Antisense Retinal Disorders Therapeutics Market, 2007 ($ Millions)
Table 67 Potential Market For Antisense Therapeutics, 2007 ($ Millions)
Table 68 Developer Of Drug Discovery Antisense Applications
Table 69 U.S. Antisense And Related Technology Patents
Table 70 Companies Developing Antisense Products
Table 71 Applications For Antisense Therapeutics
Table 72 Development Stages Of Therapeutic Agents
Table 73 Stage Of Development Of Antisense Products
Table 74 Company And Type Of Antisense Products
Table 75 Antisense Patent Portfolio Of Aegera Therapeutics
Table 76 Antisense Patent Portfolio Of Angiogene
Table 77 Antisense Patent Portfolio Of Antisense Pharma
Table 78 Antisense Patent Portfolio Of Avi Biopharma
Table 79 Antisense Patent Portfolio Of Epigenesis
Table 80 Antisense Patent Portfolio Of Genta
Table 81 Antisense Patent Portfolio Of Hybridon
Table 82 Antisense Patent Portfolio Of Immusol
Table 83 Antisense Patent Portfolio Of Isis Pharmaceuticals
Table 84 Antisense Patent Portfolio Of Lorus Therapeutics
Table 85 Antisense Patent Portfolio Of Methylgene
Table 86 Antisense Patent Portfolio Of Ribozyme Pharmaceuticals

List Of Figures

Summary Figure:
Distribution Antisense Therapeutics Market Value By Application, 2007 ($ Millions)
Figure 1 Signaling To Begin Expression Of A Gene
Figure 2 Unwinding And Separation Of Dna Strands
Figure 3 Rna Transcription
Figure 4 Rna Splicing
Figure 5 Translation Of A Protein
Figure 6 Hybridization Of Antisense Oligo To Mrna
Figure 7 Hybridized Oligo Interferes With Splicing
Figure 8 Antisense Oligo Inhibition Of Ribosomes
Figure 9 Rnase H Digestion Of Rna-Dna Duplex
Figure 10 Structure Of Dna And Rna
Figure 11 First Generation Of Antisense Molecules
Figure 12 Second Generation Antisense Modifications
Figure 13 Ribozymes
Figure 14 Number Of Antisense Scientific Publications, 1973-2002
Figure 15 Incidence Of Types Of Cancers, 2002, 2002 And 2007 (Number Of Cases)
Figure 16 Prevalence Of Immunological Disorders, 2002, 2002 And 2007 (Thousand Cases)
Figure 17 Prevalence Of Viral Disease, 2000, 2002 And 2007 (Thousand Cases)
Figure 18 Prevalence Of Retinal Disorders, 2000, 2002 And 2007 (Thousand Cases)
Figure 19 Worldwide Distribution Of Developers Of Antisense Therapeutics, 2002 (%)
Figure 20 Distribution Of Antisense Therapeutics By Application, 2002 (%)
Figure 21 Distribution Of Antisense Products Development Stage (%)